CN109731148B - Antibacterial heat conduction material - Google Patents

Antibacterial heat conduction material Download PDF

Info

Publication number
CN109731148B
CN109731148B CN201910067363.XA CN201910067363A CN109731148B CN 109731148 B CN109731148 B CN 109731148B CN 201910067363 A CN201910067363 A CN 201910067363A CN 109731148 B CN109731148 B CN 109731148B
Authority
CN
China
Prior art keywords
antibacterial
graphene oxide
coating
solution
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910067363.XA
Other languages
Chinese (zh)
Other versions
CN109731148A (en
Inventor
李建辉
杨子江
郑俊
辛立明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiaxing Laipusheng Medical Technology Co ltd
Original Assignee
Jiaxing Laipusheng Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaxing Laipusheng Medical Technology Co ltd filed Critical Jiaxing Laipusheng Medical Technology Co ltd
Priority to CN201910067363.XA priority Critical patent/CN109731148B/en
Publication of CN109731148A publication Critical patent/CN109731148A/en
Application granted granted Critical
Publication of CN109731148B publication Critical patent/CN109731148B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The invention provides an antibacterial heat-conducting coating which is characterized by comprising graphene oxide and antibacterial peptide, wherein the mass ratio of the graphene oxide to the antibacterial peptide is 1:25-1: 75. The antibacterial heat-conducting coating can reduce postoperative infection of organ transplantation, can provide stable internal environment for organs, and has good market prospect and social public value.

Description

Antibacterial heat conduction material
Technical Field
The invention belongs to the technical field of antibacterial material manufacturing, and particularly relates to an antibacterial heat-conducting coating.
Background
During the transplantation of organs, mechanical perfusion apparatuses are generally used for preserving the organs, and the working principle of the mechanical perfusion preservation apparatuses is to apply controllable continuous preservation liquid to eliminate metabolites and provide nutrients and oxygen for organs, in other words, the simulation of the internal environment of the perfusion apparatus is the key of the successful preservation of the isolated organs. Therefore, the temperature stability inside the perfusion apparatus, and the biocompatibility and antibacterial property of the material inside the perfusion apparatus play an important role in the survival and function of the organ. Conventional perfusion instruments typically use resin as the case design material. Although the resin has a good heat insulation effect and reduces the influence of the external environment temperature, the process of pouring the perfusate inside also brings the change of the temperature, and the temperature control system of the perfusion instrument is easy to have large inertia, large time lag and nonlinear temperature change when controlling the temperature inside due to the poor heat conduction efficiency of the resin, thereby influencing the state of organs. Meanwhile, for preventing bacterial infection, antibiotics such as carbapenems, tigecycline, polymyxins, fosfomycin, aminoglycosides, fluoroquinolones, β -lactams against pseudomonas, sulbactam-containing preparations, and the like have been conventionally added to perfusate, but the conventional antibiotics have been faced with the problem of bacterial resistance both when used in perfusate and when applied to patients after surgery.
At present, researches on the distribution of pathogenic bacteria of infection after organ transplantation find that the pathogenic bacteria of infection after operation are gram negative (G)-) The bacteria are abundant, and the common isolates are Klebsiella Pneumoniae (KP), Pseudomonas aeruginosa, Escherichia coli, stenotrophomonas maltophilia, and gram-positive (G)+) The most common of these bacteria, followed by enterococcus faecium. For the treatment of post-transplantation infection, the combination use of antibiotics is usually adopted, for example, the infection of enterobacteriaceae with mild and moderate extended spectrum beta-lactamase can be combined with the drug sensitive result to select piperacillin/tazobactam, cefoperazone/sulbactam and the like, and when the curative effect is poor, the drug sensitive result can be changed into carbapenems; carbapenems are preferred for severe infection, and the carbapenems can be reduced to beta-lactam antibacterial agents/beta-lactamase inhibitor mixture after being clinically stable. However, with the continuous use of antibiotics, the infected bacteria develop severe drug resistance, which results in poor post-operative treatment with antibiotics.
Graphene is a two-dimensional crystal with a thickness of a monoatomic layer formed by arranging carbon atoms in a six-membered ring. In 2004, single-layer graphene was successfully isolated from graphite by Novoselov and geom, after which graphene became the focus of much attention in the scientific community. The optical, electrical and thermal properties of graphene are remarkable, which has attracted great interest in various scientific fields, and nowadays, significant progress has been made in many aspects (e.g., nanoelectronic devices, transparent conductive films) [4-5 ]. Research on single-layer Graphene has also attracted attention to other carbon-based materials, with Graphene Oxide (GO) being the most attractive. GO is a graphene derivative with an oxygen-containing functional group, and is obtained by oxidizing graphite under an acidic condition, and a basal plane and an edge of the graphite have hydroxyl, epoxy and carboxyl. GO has good water dispersibility and can be stably dispersed in some organic solvents, oxygen-containing functional groups on the basal plane and the edges of GO enrich the surface activity of graphene, so that graphene is easy to modify and functionalize, and has huge specific surface area and good biocompatibility, so that GO has more potential advantages than other carbon-based materials, and the unique attractive properties make GO very suitable for being applied to the biomedical field and become one of the most promising materials at present. The prior art reports that antibacterial substances such as silver ions loaded on graphene can be prepared into a coating to achieve an antibacterial effect, but inorganic substances have a poor antibacterial effect.
In the nineties of the twentieth century, biologists discovered that the immune system of natural silkworm pupae produced a polypeptide substance that had bactericidal activity when induced with microorganisms. Scientists name this polypeptide as Ceropins (cephalopins), which are officially recognized as the first antimicrobial peptide in the world. Since then, the natural immunity of organisms has attracted the research and attention of vast scholars. In short decades, natural antibacterial peptides of different species have been discovered from microorganisms, animals and plants, human bodies, and the like. At present, the number of natural antimicrobial peptides found is far more than 1000. The number of amino acid residues of the natural antibacterial peptide is generally 15-50, and the natural antibacterial peptide has the advantages of high stability after heating, good solubility in water and the like. The antibacterial peptide is widely distributed in nature and has broad-spectrum antibacterial property, many antibacterial peptides not only have the bactericidal effect on gram-negative bacteria and gram-positive bacteria, but also have certain inhibiting effect on certain fungi, protists, even tumor cells and viruses, and part of natural antibacterial peptides have small toxic and side effects on eukaryotic cells. Due to the unique antibacterial mechanism, the antibacterial agent is not easy to induce the drug resistance of bacteria, and is expected to become a novel antibacterial agent with great development potential. At present, in the prior art, few researches on the antibacterial peptide loaded on graphene are carried out, and researches on the antibacterial purpose of the coating prepared by the antibacterial peptide loaded on graphene are reported, and whether the coating can be used for a perfusion system for organ transplantation or not belongs to a blank research in the prior art.
Therefore, it is an urgent problem to obtain an antibacterial heat-conducting coating which stabilizes the internal temperature of an organ perfusion system and can prevent bacterial infection during organ perfusion, thereby inhibiting infection after transplantation.
Disclosure of Invention
In order to solve the problems that postoperative infection is easy to occur in organ transplantation operation, infected bacteria has strong drug resistance, the treatment effect is poor by using antibiotics and the stability of the internal temperature is not high in the working process of a mechanical perfusion system in the prior art, the invention provides an antibacterial heat-conducting coating which is characterized in that the antibacterial heat-conducting coating comprises graphene oxide and antibacterial peptide, and the mass ratio of the graphene oxide to the antibacterial peptide is 1:25-1: 75.
In one embodiment, the graphene oxide is reduced graphene oxide, which is obtained by reacting graphene oxide with hydrazine monohydrate.
In one embodiment, the antimicrobial peptide is a fusion polypeptide, preferably a fusion polypeptide of cecropin a and cecropin. Cecropin A (cecropin A) is derived from silkworm, is cationic antimicrobial peptide, has a protein structure of a amphiphilic alpha helical structure, has broad-spectrum bactericidal capability and good thermal stability, and has no killing effect on normal cells. The research finds that the N-terminal sequence of cecropin A has an important effect on the antibacterial activity of cecropin A. The sequence of cecropin a is RWKIFKKIEK MGRNIRDGIV KAGPAIEVLG SAKAI (35 amino acids total). The death hormone (Thanatin) is a small molecular antibacterial peptide found in insect spotted-belly stinkbugs (Podisumasculiniviventris), has a simple structure, and has an inhibiting effect on gram-positive bacteria, gram-negative bacteria and certain fungi. The sequence of the deamin is GSKKPVPIIY CNRRTGKCQR M (21 amino acids in total). Fusion of the 1 st to 7 th amino acid residues of cecropin A and the 4 th to 19 th amino acid residues of mortin to prepare fusion polypeptide with the sequence of RWKIFKKKPV PIIYCNRRTG KCQ (23 amino acids in total). The fusion polypeptide has good inhibition effect on Acinetobacter baumannii, Klebsiella oxytoca, Pseudomonas aeruginosa, Burkholderia cepacia, Klebsiella pneumoniae, Staphylococcus aureus and other bacteria (expression and activity research of composite antibacterial peptide in Pichia pastoris, Yang Gui Mao and the like, journal of International inspection medicine, 6 months in 2018, 12 th vol.39, 1439-.
In one embodiment, the fusion polypeptide is a derivative of a fusion polypeptide (RWKIFKKKPV PIIYCNRRTG KCQ) of cecropin a and decetin, preferably a sequence with 60%, 70%, 80%, 90%, 95%, 99% identity to the fusion polypeptide, or a sequence with one or more, e.g., 2, 3, 4, 5, amino acid mutations.
Generally, an antibacterial peptide containing arginine has higher antibacterial activity than an antibacterial peptide containing lysine, and an antibacterial peptide containing tryptophan is more effectively bound to a bacterial cell membrane than an antibacterial peptide containing phenylalanine. This is probably because arginine is more delocalised at the positive charge on the amino group than lysine, and is likely to enhance electrostatic attraction with negatively charged bacterial membranes. Thus, in one embodiment, the lysine (K) at position 3, 7, 8 of the cecropin a and decetin fusion polypeptide (RWKIFKKKPV PIIYCNRRTG KCQ) sequences is replaced with arginine (R) and the phenylalanine (F) at position 5 is replaced with tryptophan (W) to obtain the antimicrobial peptide: RWRIWKRRPV PIIYCNRRTG RCQ are provided.
In one embodiment, the antimicrobial peptide is prepared by means of polypeptide synthesis, such as liquid phase synthesis, solid phase synthesis, Fmoc, tBoc, etc., or using a polypeptide synthesizer, such as ABI336, ABI, USA. The recombinant expression can also be carried out in host cells by adopting the conventional genetic engineering operation in the field, for example, the recombinant expression can be carried out in a yeast expression system, such as the method disclosed in the literature, "expression of the composite antibacterial peptide in pichia pastoris and activity research thereof", Yang Gui Mao et al, International inspection medical journal, 6 months in 2018, volume 39, 12 th stage, 1439-.
In one embodiment, an antibacterial heat-conducting material is provided, wherein the antibacterial heat-conducting material is formed by coating an antibacterial heat-conducting coating on a heat-conducting material, preferably, the heat-conducting material is a metal material, and more preferably, the heat-conducting material is an aluminum alloy.
In one embodiment, the preparation method of the antibacterial heat conduction material comprises the following steps:
1) immersing the heat conducting material in 2mg/ml dopamine hydrochloride solution, controlling the pH value to be 8-8.5, reacting for 16 hours at normal temperature, fully cleaning with distilled water, drying, and repeating the steps for three times to obtain the polydopamine coating;
2) immersing the material prepared in the step 1) into a polylysine solution of 5mg/ml for reaction for 3-6 hours, washing with distilled water, and drying to obtain a polylysine coating;
3) reacting graphene oxide with hydrazine monohydrate to obtain reduced graphene oxide, preparing the reduced graphene oxide into 0.1mg/ml solution, and adding the solution into 2.5mg/ml antibacterial peptide solution, wherein the volume ratio of the reduced graphene oxide to the antibacterial peptide is 1:1-1: 4; fully mixing for 2-4h, centrifuging and re-dispersing to obtain a reduced graphene oxide solution loaded with antibacterial peptide;
4) immersing the material prepared in the step 2) in the solution prepared in the step 3), adsorbing for 15-45min, and cleaning with distilled water to obtain a single-layer reduced graphene oxide coating carrying antibacterial peptide; and (4) repeating the step 4) for 4-6 times, preferably 5 times, and covering a plurality of layers of reduced graphene oxide coatings loaded with antibacterial peptides on the heat conduction material.
Preferably, the volume ratio of the reduced graphene oxide to the antibacterial peptide is 1: 2.5.
In one embodiment, the antibacterial heat-conducting coating or the antibacterial heat-conducting material is used for preparing an organ mechanical perfusion system or an organ mechanical perfusion apparatus, preferably, the organ is selected from heart, organ, kidney, pancreas and bone marrow.
Compared with the prior art, the invention has the following advantages: the coating is prepared by loading antibacterial peptide on graphene oxide, and the graphene has good thermal conductivity, so that a temperature control system can rapidly control the internal temperature, the temperature fluctuation is reduced, and a good temperature environment is provided for organs. The graphene oxide has high biocompatibility, is nontoxic and harmless to cells, has a good inhibition effect on pathogenic bacteria and does not have a drug resistance problem due to the loaded antibacterial peptide, and prevents organs from being infected by the pathogenic bacteria in the perfusion process. The antibacterial heat-conducting coating or the antibacterial heat-conducting material can prevent postoperative infection, can provide stable internal environment for organs, and has good market prospect and social public value.
Drawings
FIG. 1: SEM images of the surface morphology and fracture tissue morphology of the graphene oxide loaded antibacterial coating, wherein FIG. 1a is the surface morphology, and FIG. 1b is the fracture tissue morphology;
FIG. 2: bacterial colony maps of the plates cultured on the GO-CT-1-C coating surface and the control group surface, wherein the bacterial colony map of the plate cultured on the pseudomonas aeruginosa control group surface is shown in figure 2 a; FIG. 2b is a plate colony map of Pseudomonas aeruginosa after GO-CT-1-C coating surface culture; FIG. 2c is a plate colony diagram of Klebsiella pneumoniae after surface culture in a control group; FIG. 2d is a plate colony map of Klebsiella pneumoniae after culture on the GO-CT-1-C coating surface; FIG. 2e is a colony map of a plate after surface culture of a control group of Staphylococcus aureus; FIG. 2f is a plate colony map of Staphylococcus aureus after GO-CT-1-C coating surface culture;
FIG. 3: a fluorescence staining pattern of endothelial cells after GO-CT-1-C coating surface culture;
FIG. 4: the present invention is a schematic of a mechanical perfusion system for organ preservation, wherein 1: central processor assembly, 2: peristaltic pump, 3: organ perfusate reservoir, 4: input catheter C, 5: membrane oxygenator, 6: input catheter a, 7: input catheter B, 8: organ storage device, 9: output duct a, 10: perfusate filter equipment, 11: an output conduit B; 12: liquid collecting device, 13: liquid meter, 14: organ normothermic mechanical perfusion system, 15: monitoring data collection device, 16: temperature sensor, 17: pressure sensor, 18: flow rate sensor, 19: data processing apparatus, 20: control assembly, 21: an information transmission device;
FIG. 5: liver perfusate storage or liver storage device result schematic diagram, wherein, 22: cold and hot adjustment pipe, 23: ABS resin, 24: aluminum alloy, 25: coating GO-CT-1-C.
Detailed Description
The following is a detailed description of the configuration and effects of the mechanical perfusion system for organ preservation according to the present invention, but the following should not be construed as limiting the scope of the present invention.
EXAMPLE 1 preparation of Complex antimicrobial peptides
The mutant composite antibacterial peptide is synthesized by adopting a polypeptide synthesis method, and the synthesized polypeptide is named as CT-1. The polypeptide is synthesized by adopting an F-moc full-automatic solid-phase synthesis method, which comprises the following steps:
1.1 Synthesis of the polypeptide
Protected polypeptides were assembled on resin using a model of 433A automated synthesizer (ABI, Foster City, CA). The peptide resin was incubated in suspension for 2.5 hours at room temperature to deprotect. The suspension system consisted of 10ml TFA, 0.75 g phenol, 0.25 ml 1, 2-ethanedithiol, 0.5 ml thioanisole and 0.5 ml water. The resin was isolated from the polypeptide deprotection group mixture by filtration. The crude polypeptide was precipitated in 150ml of a precooled ether solution and purified by chromatography on a sephadex G-25 column using 10% glacial acetic acid as eluent. Subsequently, the polypeptide-containing fractions are pooled and lyophilized, and the crude polypeptide is about 80% pure using high performance liquid chromatography.
1.2 polypeptide purification and characterization
The filtrate was directly applied to a C18 liquid chromatography column from Zorba using a preparative high performance liquid chromatography pump (Waters 2000 series, Milford, MA). The C18 column was pre-washed with buffer A (0.1% TFA in water) followed by a 40 min linear gradient elution with 10-40% buffer B (0.1% TFA in acetonitrile) at 8 mL/min. The resulting fraction was a 90% CT-1 concentrate which was subsequently further purified by semi-preparative reverse phase high performance liquid chromatography on a 9.4 x 250mm Zorbax C18 liquid chromatography column. Finally, the final product was converted from TFA salt solution to acetate solution in sephadex G-25 column using 20% acetic acid solution as eluent. The purity of the polypeptide was evaluated by analytical reverse phase high performance liquid chromatography, and the purity of the final product, polypeptide, was 98%.
The sequence composition of the polypeptides was determined using an Ultraflex III TOF/TOF mass spectrometer. The sequences of the prepared polypeptides are shown in Table 1,
table 1: preparation of the obtained polypeptide sequence
Name (R) Sequence of
CT-1 RWRIWKRRPV PIIYCNRRTG RCQ
Example 2 preparation of Heat conductive Material covering graphene oxide-loaded antibacterial peptide coating
In the implementation, the reduced graphene oxide loaded antibacterial peptide coating is prepared firstly, and the coating is coated on the surface of the heat conducting material in a self-assembly mode, wherein the heat conducting material is an aluminum alloy, so that an aluminum alloy material covering the graphene oxide loaded antibacterial peptide coating is obtained, and the specific preparation method is as follows:
2.1 surface modification of thermally conductive materials
Immersing the cleaned and dried aluminum alloy in 2mg/ml dopamine hydrochloride solution, adjusting the pH value to 8.5 by NaOH, reacting overnight at normal temperature, drying at room temperature, repeating the steps for three times to enable the surface of the aluminum alloy to be modified with polydopamine, immersing the aluminum alloy material modified with polydopamine in 5mg/ml polylysine solution for reacting for 5 hours, taking out, fully cleaning by distilled water, and drying at room temperature to obtain the aluminum alloy material modified with polylysine.
2.2 preparation of reduced graphene oxide solution loaded with antibacterial peptide
Firstly, preparing 0.1mg/ml graphene oxide solution, adding 1mg hydrazine monohydrate into 100ml graphene oxide solution, fully stirring for reaction for 2 hours at 80 ℃, carrying out centrifugal drying to obtain reduced graphene oxide, and carrying out ultrasonic dispersion again to obtain 0.2mg/ml solution;
preparing the composite antibacterial peptide prepared in the embodiment 1 into a composite antibacterial peptide solution of 2.5mg/ml, adding a reduced graphene oxide solution into the composite antibacterial peptide solution, wherein the volume ratio of reduced graphene oxide to antibacterial peptide is 1:1-1: 4; and after fully mixing for 3.5h, centrifuging and re-dispersing to obtain the composite antibacterial peptide-loaded reduced graphene oxide solution.
2.3 preparation of heat conduction material covering graphene oxide loaded antibacterial peptide coating
Immersing the aluminum alloy material modified with polylysine on the surface prepared in the step 2.1 into the solution prepared in the step 2.2, adsorbing for 30min at room temperature, cleaning with distilled water, and drying to obtain a single-layer reduced graphene oxide coating carrying antibacterial peptide; repeating the step for 5 times to obtain the aluminum alloy material with the surface covered with a plurality of layers of reduced graphene oxide coatings loaded with antibacterial peptides.
2.4 Scanning Electron Microscope (SEM) analysis
The JSM-6700F field emission scanning electron microscope is adopted to observe the surface morphology of the graphene oxide coating prepared in the step 2.3 and the morphology structure of fracture tissues (the accelerating voltage is 10 kV). Before testing, the surface of the sample is sprayed with gold.
As shown in fig. 1, the surface formed by the aluminum alloy material is covered with a plurality of layers of reduced graphene oxide coatings loaded with antibacterial peptides, and the characteristic folded structure of graphene oxide can be observed, and the graphene oxide coatings have sharp edges; as can be seen from the fracture structure form, a coating with a certain thickness is formed on the surface of the aluminum alloy material.
Example 3 comparison of antibacterial effects of coatings prepared from composite antibacterial peptide and graphene oxide at different ratios
In this embodiment, in order to explore the antibacterial effect of the coating prepared from the composite antibacterial peptide and the graphene oxide in different proportions, the optimal concentration ratio of the composite antibacterial peptide to the graphene oxide is found, and the volume ratio of the composite antibacterial peptide to the reduced graphene oxide is 1:1, 1:2, 1:2.5, 1:3, the corresponding coated aluminum alloy material GO-CT-1-A, GO-CT-1-B, GO-CT-1-C, GO-CT-1-D was prepared by the method of example 2, and the experimental setup control was an uncoated aluminum alloy material, specifically as shown in table 2: preparation of coatings with different antibacterial peptide and graphene ratios
Figure BDA0001956156040000081
3.1 measurement of antibacterial Properties
The antibacterial property of GO-CT-1-A, GO-CT-1-B, GO-CT-1-C, GO-CT-1-D and a control group is measured by a flat plate counting method, and the method comprises the following specific steps:
the antibacterial property of the sample is tested by taking pseudomonas aeruginosa, klebsiella pneumoniae and staphylococcus aureus (s. All glassware, Phosphate Buffered Saline (PBS), was autoclaved at 120 ℃ prior to each antimicrobial experiment.
200 μ L of 106The bacterial solution of cfu/mL is respectively dripped on GO-CT-1-A, GO-CT-1-B, GO-CT-1-C, GO-CT-1-D, so that the bacterial solution is spread on the surface of a sample, and then ultrasonic shaking culture is carried out for 3h at 37 ℃.
Washing off bacteria on the surface of the sample after ultrasonic oscillation culture by using 10mL of PBS, uniformly coating 100 mu L of washed bacteria solution on the surface of a solid culture medium, placing the solid culture medium in a constant-temperature incubator at 37 ℃, culturing for 18-24 h, observing the growth condition of bacterial colonies on the surface of the culture medium, and evaluating the antibacterial performance of the coating in the ratio of the antibacterial peptide to the graphene.
The specific experimental results are shown in Table 3 and FIG. 2
Table 3: comparison of bacteriostatic rates of coatings with different proportions
Figure BDA0001956156040000091
As can be seen from the results in table 3, compared with the control group, the heat conductive material coated with the antibacterial peptide and the graphene oxide coating has a better antibacterial effect on both gram-negative bacteria and gram-positive bacteria, and particularly, the antibacterial coating prepared with the antibacterial peptide and the graphene oxide at a mass ratio of 1:62.5 has an antibacterial rate of more than 90% on both gram-negative bacteria and a antibacterial rate of about 70% on gram-positive bacteria, so that a better effect is obtained.
Example 4 biocompatibility testing of GO-CT-1-C
In this embodiment, in order to detect the biocompatibility of the antimicrobial peptide and the graphene oxide coating, a heat conductive material coated with the antimicrobial peptide and the graphene oxide coating prepared in a mass ratio of 1:62.5 is used as a substrate, endothelial cells are cultured, and the growth condition of the endothelial cells is further observed by using a live-dead cell staining reagent, which includes the following specific experimental operations.
4.1 cytotoxicity assays
Cells were divided by 2 x 104The cell density of the cell is inoculated on the surface of the heat conduction material covered with the coating, the cell is cultured for 3 days, the cell is rinsed with PBS for three times after the culture is finished, the cell is stained with a staining agent in a constant temperature incubator at 37 ℃ in a dark place for 1 hour, the cell is rinsed with PBS for 2 times after 1 hour, and then the cell is observed by a laser scanning confocal microscope and photographed.
4.2 results of the experiment
As shown in FIG. 3, it can be seen that the growth of endothelial cells on the surface of the coating is good, and no dead cells are observed, which indicates that the coating has no obvious influence on the normal growth and propagation of endothelial cells, and the coating is preliminarily judged to have no obvious cytotoxic effect on endothelial cells.
Example 5 preparation of organ perfusion System Using GO-CT-1-C coated thermally conductive Material
In this embodiment, the organ perfusion system is prepared by using the heat conducting material coated with GO-CT-1-C, and the perfusion system can be applied to ex vivo normal temperature mechanical perfusion of liver, and is specifically configured as follows:
as shown in fig. 4 and 5, in the perfusion system 14, the central processor assembly 1 is connected to the peristaltic pump 2, the output power of the peristaltic pump 2 is controlled by the control assembly 20 in the central processor assembly 1, the peristaltic pump 2 controls the perfusion pressure and flow rate of the perfusion fluid through the change of the output power, further, the peristaltic pump 2 is connected to the liver perfusion fluid storage 3, the liver perfusion fluid storage 3 is formed by an inner layer and an outer layer, and the interlayer is provided with the cold and hot adjusting tube 22. The outer layer is prepared from ABS resin 23. The inner layer is made of an aluminum alloy 24, and the cavity-facing side of the inner layer is coated with the coating GO-CT-1-C25 prepared in example 3, and the specific structure is shown in FIG. 5. The cold and hot adjusting pipe 22 is controlled by the control component 20 and is used for adjusting the temperature of the perfusate; a temperature sensor 16 is arranged in the liver perfusate storage 3 and used for monitoring the temperature of the liver perfusate; the liver perfusate storage 3 is connected with the membrane oxygenator 5 through an input conduit C4, a flow rate sensor 18 is arranged between the liver perfusate storage 3 and the membrane oxygenator 5 and is used for monitoring the total flow rate of the liver perfusate, and the oxygenation efficiency of the membrane oxygenator 5 is controlled by a control component 20 in the central processing unit component 1; the membrane oxygenator 5 is connected with the liver storage device 8 through an input conduit A6 and an input conduit B7, wherein the input conduit A6 is a hepatic artery perfusion conduit, and a flow rate sensor 18 and a pressure sensor 17 are arranged on the hepatic artery perfusion conduit and are used for monitoring the perfusion flow rate and the perfusion liquid pressure of the hepatic artery; the input catheter B7 is a portal vein input catheter, and is also provided with a flow rate sensor 18 and a pressure sensor 17 for monitoring the flow rate of portal vein perfusion and the pressure of perfusate; an opening is arranged in the liver storage device 8, and the input conduit A6 and the input conduit B7 can enter the interior of the liver storage device 8 and be connected with the liver preserved in vitro. The liver storage device 8 is divided into an inner layer and an outer layer, and a cold and hot adjusting pipe 22 is arranged in the interlayer. The outer layer is prepared from ABS resin 23. The inner layer is made of an aluminum alloy 24, and the cavity-facing side of the inner layer is coated with the coating GO-CT-1-C25 prepared in example 3, and the specific structure is shown in FIG. 5. The cold and hot regulating tube 22 is controlled by the control assembly 20 and is used for regulating the internal environment temperature of the liver storage device 8; a temperature sensor 16 is provided in the liver storage device 8 for monitoring the internal ambient temperature.
The liver storage device 8 is connected with the perfusate filtering device 10 through an output conduit A9, an opening is arranged in the liver storage device 8, and the output conduit A9 can enter the interior of the liver storage device to be connected with the liver preserved in vitro; the perfusate filtering device 10 is connected with the liver perfusate storage 3 and returns the filtered perfusate to the liver perfusate storage 3; the liver storage device 8 is connected with the liquid collecting device 12 through an output conduit B11 and is used for collecting bile secreted by the liver during perfusion; the liquid collecting device 12 is provided with a liquid meter 13 for measuring the amount of bile secreted by the liver during perfusion.
Further, the perfusion system 14 is provided with a monitoring data collecting means 15, said monitoring data collecting means 15 collecting monitoring data generated by the temperature sensor 16, the pressure sensor 17 and the flow rate sensor 18 and the liquid meter 12 and transmitting the collected data to the central processor assembly 1. The central processing unit assembly 1 is provided with a data processing device 19 for processing the monitoring data collected by the monitoring data collecting device 15, and the central processing unit assembly 1 further comprises an information transmission device 21 which can transmit the data parameter processing result of the data processing device 19 to an external corresponding receiving device.
Example 6 temperature stability testing of organ perfusion systems
In this embodiment, in order to examine the stability of the internal temperature of the organ perfusion system prepared by coating the aluminum alloy material in embodiment 5, the internal temperature of the liver storage device and the liver perfusate storage device in the perfusion process is monitored, and the fluctuation of the temperature in the perfusion process is compared, specifically as follows:
6.1 Experimental methods
The normal-temperature liver perfusate of the naringenin derivative is used as a testing perfusate, and the set temperature of a perfusion system is as follows: 4 ℃, 20 ℃, 36.5 ℃, the ambient temperature is the indoor ambient temperature, about 23-26 ℃, and the total perfusion flow rate is 450 ml/min.
After the perfusion system is started for 10min, the internal temperature of the liver storage device and the liver perfusate storage device is monitored, the temperature is detected once every 10min, and the perfusion time is 1 h.
A control group was set, the perfusion system of the control group was made of an aluminum alloy material without a coating, and the other structural settings were the same as in example 5.
6.2 results of the experiment
The measured maximum and minimum temperatures for the liver storage device and the liver perfusate reservoir are shown in tables 4 and 5.
TABLE 4 maximum and minimum temperatures for liver storage devices
Figure BDA0001956156040000111
Figure BDA0001956156040000121
TABLE 5 maximum and minimum temperatures of liver perfusate reservoir
Figure BDA0001956156040000122
From the results shown in table 4 and table 5, it can be seen that, compared to the control group, the perfusion system coated with the GO-CT-1-C coating has a more stable internal temperature of the liver storage device and the liver perfusate storage device, and the temperature difference is about ± 0.1 ℃, and therefore, the graphene has good thermal conductivity, and the GO-CT-1-C coating facilitates rapid and stable heat conduction and plays a good role in stabilizing the internal temperature of the system.
EXAMPLE 7 in vitro preservation of liver Using perfusion System containing GO-CT-1-C coating
1 laboratory animal
The male Chinese miniature pig has 20 heads and the weight of 30 plus or minus 3 Kg. The groups were divided into two groups, experimental and control groups, each group having 10 heads. All experimental animals are treated by humanity, and accord with the guide for managing and using experimental animals issued by the national institutes of health.
2. Method of producing a composite material
(1) The experimental animals are fasted and water is forbidden for 8 hours before operation. Pentobarbital sodium is injected into muscles for induction anesthesia, and the weight is weighed and recorded. Fixing the supine four limbs on an operating table, absorbing oxygen at high flow, preparing skin, connecting with precordial lead ECG monitor, and connecting pigtail end with oxyhemoglobin saturation probe. Establishing peripheral venous access through ear vein by scalp needle, fully fixing, inducing anesthesia with 1mg/kg of succinylcholine chloride injection before trachea intubation, connecting an anesthesia machine for ventilation after judging that the scalp needle is inserted into a correct position, and keeping the ratio of inhalation to exhalation of 1:2. Through the peripheral venous access, vecuronium bromide is interrupted to maintain muscle relaxation, and propofol is given to maintain anesthesia.
(2) Liver acquisition: the crisscross incision enters the abdominal cavity layer by layer, the liver duodenal ligament is dissected, the ligamentum duodenale is ligated after dissociating out of the common bile duct, the catheter is inserted at the near end, the hepatic artery and the portal vein are separated and suspended, and the whole hepatic artery is completely dissociated. And the spleen vein is dissociated, the inferior hepatic vena cava is dissociated after the spleen vein dissociation is completed, and then the superior hepatic vena cava is dissociated. After successful dissociation, intubation is carried out from the spleen vein to the portal vein, the abdominal aorta is dissociated, intubation is carried out after the abdominal aorta is dissociated, 12500 units of intravenous heparin are used for whole body heparinization, after the heparinization is completed, liver perfusion is carried out, the perfusion volume of UW liquid through the portal vein is about 500ml, the perfusion volume of the abdominal aorta is about 1000ml, and the biliary tract is flushed by about 150 ml. And (3) continuously covering sterile ice chips on the surface of the liver in the perfusion process to help the liver to cool and perfuse, then cutting the liver, and putting the liver into a sterile basin filled with a 4 ℃ protective solution for trimming.
(3) Preheating of the mechanical perfusion system: the system is started to maintain the perfusate temperature and the liver storage chamber temperature at 36.5 ℃, and the perfusion preservation system is operated to wait for the liver supply.
(4) The isolated liver was connected to the perfusion system, wherein the experimental group was connected to the mechanical perfusion system prepared in example 5, the perfusion system of the control group was prepared from an aluminum alloy material without a coating, and the other structural arrangements were the same as those in example 5.
(5) And (3) perfusion preservation: after the connection is finished, the hepatic artery pressure is adjusted to be 80-120 mm Hg, the portal vein pressure is adjusted to be 10-20 mm Hg, the total perfusion flow is kept at 400-. The flow and pressure of the portal vein and the hepatic artery are respectively monitored by the pressure sensor and the flow velocity sensor in real time, the output power of the peristaltic pump is adjusted to maintain the set perfusion pressure and flow velocity, and the portal vein and arterial blood flow is maintained within the design range. Discharging 400ml of perfusate by equivalent replacement every 3h, adding 400ml of fresh perfusate, and perfusing naringenin derivative normal temperature liver perfusate for 4 h.
Example 8 Ex vivo preservation of organ transplantation and postoperative infection
To further examine the postoperative infection status of ex vivo liver transplantation in example 7, the liver after 4h perfusion was transplanted as follows:
8.1 Experimental animals
The male Chinese miniature pig has 20 heads and the weight of 30 plus or minus 3 Kg. Two groups of 10 per group were randomized as recipients for liver transplantation, with group a: receiving liver transplantation of an experimental group; group B: a control group liver transplant was received.
8.2 transplantation method
Fixing a receptor pig, anesthetizing, preparing skin, disinfecting, paving a towel, enabling a human-shaped incision to enter an abdominal cavity layer by layer, dissecting a common bile duct, a hepatic artery and a portal vein, suspending after the dissection is finished, beginning to dissect the superior and inferior hepatic vena cava, dissociating the hepatic artery, sequentially blocking and cutting off the hepatic artery (entering a no-liver stage), the portal vein, the inferior and superior and inferior hepatic vena cava, and rapidly implanting a donor liver after organs are removed; the anastomosis of the superior vena cava and the inferior vena cava of the liver is started immediately, after the anastomosis is finished, the portal vein is flushed and anastomosed, the portal vein and the semi-open superior vena cava of the liver are opened, the superior vena cava and the inferior vena cava of the liver are fully opened after the vital signs are monitored to be relatively stable (no liver period is finished), the inferior vena cava and the hepatic artery are opened after the anastomosis is finished, the bile is secreted out from an organ (the new liver function is recovered) after the vital signs are relatively stable, the common bile duct is anastomosed, the T-shaped tube is retained to drain the bile, the abdomen is closed layer by layer, the abdomen is closed, the bile is drained by the T-shaped tube, the vital signs are relatively stable, the operation is finished, the vital signs are monitored, appropriate amount of antibiotics and hormones and corresponding energy.
8.3 detection method of organ status after transplantation
After transplantation, the experimental group and the control group are subjected to conventional antibiotic anti-infection treatment (Rogowski) and triple immunosuppressive treatment of PufuCola, CellCet and prednisone, and after 7 days of transplantation, whole blood, phlegm, bile, ascites and tracheal secretion of the experimental group and the control group of the transplanted organs are respectively extracted, and subjected to pathogenic bacteria culture separation and drug sensitivity test. The bacterial culture apparatus was purchased from bioton merieux, usa, and the bacterial identification was performed using a semi-automatic analyzer purchased from becton dinson, usa and an API system of the french biological merriee. When the positive strains which are more than or equal to 2 times and are the same strains continuously appear, the combined bacterial infection after the liver transplantation can be diagnosed.
8.4 results of the experiment
15 bacteria were isolated from the specimens from the liver-transplanted pigs of the experimental group, as shown in Table 6.
TABLE 6 test group of the bacterial detection of the positive specimen of the porcine liver transplantation
Figure BDA0001956156040000141
Figure BDA0001956156040000151
29 strains of bacteria were isolated from control liver transplant pig specimens, as shown in Table 7.
TABLE 7 control group of positive specimen for pig liver transplantation bacteria detection
Figure BDA0001956156040000152
As can be seen from the results in tables 6-7, the perfusion system containing the GO-CT-1-C coating is less than the control group in both the type and the number of infectious bacteria, and has a significant inhibitory effect particularly on Pseudomonas aeruginosa and Klebsiella pneumoniae among gram-negative bacteria, which indicates that the GO-CT-1-C coating is advantageous in preventing postoperative infection of organ transplantation.
The invention has been described in detail with respect to a general description and specific embodiments thereof, but it will be apparent to those skilled in the art that modifications and improvements can be made based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
SEQUENCE LISTING
<110> Jiaxing laipu sanden medical science and technology limited
<120> antibacterial heat conduction material
<130> CP11902069C
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 35
<212> PRT
<213> cecropin A
<400> 1
Arg Trp Lys Ile Phe Lys Lys Ile Glu Lys Met Gly Arg Asn Ile Arg
1 5 10 15
Asp Gly Ile Val Lys Ala Gly Pro Ala Ile Glu Val Leu Gly Ser Ala
20 25 30
Lys Ala Ile
35
<210> 2
<211> 21
<212> PRT
<213> death substance
<400> 2
Gly Ser Lys Lys Pro Val Pro Ile Ile Tyr Cys Asn Arg Arg Thr Gly
1 5 10 15
Lys Cys Gln Arg Met
20
<210> 3
<211> 23
<212> PRT
<213> fusion polypeptide
<400> 3
Arg Trp Lys Ile Phe Lys Lys Lys Pro Val Pro Ile Ile Tyr Cys Asn
1 5 10 15
Arg Arg Thr Gly Lys Cys Gln
20
<210> 4
<211> 23
<212> PRT
<213> antimicrobial peptides
<400> 4
Arg Trp Arg Ile Trp Lys Arg Arg Pro Val Pro Ile Ile Tyr Cys Asn
1 5 10 15
Arg Arg Thr Gly Arg Cys Gln
20

Claims (3)

1. The antibacterial heat conduction material is characterized in that an antibacterial heat conduction coating is coated on the heat conduction material, the heat conduction material is an aluminum alloy, the antibacterial heat conduction coating comprises graphene oxide and antibacterial peptide, the antibacterial peptide is a fusion polypeptide of cecropin A and cecropin A, the sequence of the fusion polypeptide is RWRIWKRRPV PIIYCNRRTG RCQ, and the graphene oxide is reduced graphene oxide; the preparation method of the antibacterial heat conduction material comprises the following steps:
1) immersing the heat conducting material in 2mg/ml dopamine hydrochloride solution, controlling the pH value to be 8-8.5, reacting for 16 hours at normal temperature, fully cleaning with distilled water, drying, and repeating the steps for three times to obtain the polydopamine coating;
2) immersing the material prepared in the step 1) into a polylysine solution of 5mg/ml for reaction for 3-6 hours, washing with distilled water, and drying to obtain a polylysine coating;
3) reacting graphene oxide with hydrazine monohydrate to obtain reduced graphene oxide, preparing the reduced graphene oxide into 0.2mg/ml solution, adding the solution into 2.5mg/ml antibacterial peptide solution, fully mixing for 2-4h, centrifuging and re-dispersing to obtain the reduced graphene oxide solution loaded with antibacterial peptide, wherein the volume ratio of the reduced graphene oxide to the antibacterial peptide solution is 1: 2.5;
4) immersing the material prepared in the step 2) in the solution prepared in the step 3), adsorbing for 15-45min, and cleaning with distilled water to obtain a single-layer reduced graphene oxide coating carrying antibacterial peptide; and (4) repeating the step 4) for 4-6 times to obtain a plurality of layers of reduced graphene oxide coatings loaded with antibacterial peptides and covered on the heat conduction material.
2. Use of the antibacterial heat-conducting material according to claim 1, wherein the antibacterial heat-conducting material is used for preparing an organ mechanical perfusion system or an organ mechanical perfusion apparatus.
3. Use according to claim 2, wherein the organ is selected from the group consisting of heart, liver, kidney.
CN201910067363.XA 2019-01-24 2019-01-24 Antibacterial heat conduction material Active CN109731148B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910067363.XA CN109731148B (en) 2019-01-24 2019-01-24 Antibacterial heat conduction material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910067363.XA CN109731148B (en) 2019-01-24 2019-01-24 Antibacterial heat conduction material

Publications (2)

Publication Number Publication Date
CN109731148A CN109731148A (en) 2019-05-10
CN109731148B true CN109731148B (en) 2021-06-15

Family

ID=66365921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910067363.XA Active CN109731148B (en) 2019-01-24 2019-01-24 Antibacterial heat conduction material

Country Status (1)

Country Link
CN (1) CN109731148B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111529682A (en) * 2020-05-11 2020-08-14 中国人民解放军陆军军医大学第一附属医院 Chemotaxis antibacterial nano material and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105327406A (en) * 2015-11-10 2016-02-17 深圳迈德科技有限公司 Method for preparing multi-layer heparin-carrying reduced graphene oxide coating
CN105456233A (en) * 2015-11-17 2016-04-06 中国石油大学(华东) High-drug-loading-capacity long-effect slow-release antibacterial thin film and preparation method thereof
CN108902132A (en) * 2018-10-12 2018-11-30 嘉兴莱普晟医疗科技有限公司 A kind of machine perfusion system saved for isolated heart
CN109054589A (en) * 2018-08-10 2018-12-21 四川大仁新创科技有限公司 A kind of radiator that graphene heat conducting coating is modified

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105327406A (en) * 2015-11-10 2016-02-17 深圳迈德科技有限公司 Method for preparing multi-layer heparin-carrying reduced graphene oxide coating
CN105456233A (en) * 2015-11-17 2016-04-06 中国石油大学(华东) High-drug-loading-capacity long-effect slow-release antibacterial thin film and preparation method thereof
CN109054589A (en) * 2018-08-10 2018-12-21 四川大仁新创科技有限公司 A kind of radiator that graphene heat conducting coating is modified
CN108902132A (en) * 2018-10-12 2018-11-30 嘉兴莱普晟医疗科技有限公司 A kind of machine perfusion system saved for isolated heart

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
复合抗菌肽在毕赤酵母中的表达及其活性研究;杨桂茂等;《国际检验医学杂志》;20180628;第39卷(第12期);第1440页左栏第3段,第1442页右栏第2段 *

Also Published As

Publication number Publication date
CN109731148A (en) 2019-05-10

Similar Documents

Publication Publication Date Title
Balasubramaniam et al. Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice
US6251383B1 (en) Method for ex-vivo expansion of hematopoietic cells
CN1214624A (en) Improved tissue destruction in cryosurgery by use of thermal hysteresis proteins
KR20220037435A (en) Mitochondrial processing of organs for transplantation
HU202578B (en) Process for repricating bone marrow celles in three-dimension celle-cultivating systhem, three-dimension vehicle for the systhem and process for testing citotoxicity of the systhem
CN109731148B (en) Antibacterial heat conduction material
CN103333225A (en) Antibacterial peptide, preparation method and applications thereof
KR20070112205A (en) Method and composition for repairing heart tissue
CN109644988B (en) Mechanical perfusion system for relieving infection after organ transplantation
JPS5829714A (en) Serum-free and mitogene-free t cell growth factor and manufacture
CN114209814B (en) Application of TNFSF15 protein in promoting differentiation of bone marrow stem cells into macrophages and expansion
CN109511649B (en) Normal-temperature mechanical perfusion system capable of expanding liver supply source
CN109511650B (en) Normal-temperature mechanical perfusate capable of enlarging liver supply source
CN107349220A (en) A kind of preparation comprising fibroblast excretion body and application thereof
US20230210105A1 (en) Cryopreserving macrophages
CN111518187B (en) Antibacterial peptide DN6NH2 and application thereof
CN107446023B (en) Polypeptide HIP-13 capable of antagonizing RNA binding activity of HuR protein and application thereof
CN107022004B (en) Polypeptide targeting tumor cells and application thereof
CN114213521B (en) Novel cell matrix-like biological material with wet adhesion performance and application thereof
CN106831956B (en) A kind of antineoplastic polypeptide MUDP-21 and its application
CN109535241A (en) DC-CIK co-cultured cell and preparation method thereof, sensitising antigens and application
CN110615830B (en) Application of antibacterial peptide in anti-mycobacterial infection medicine
CN108721248A (en) A kind of preparation method, product and the application of pH response type nanos silver assembly
Fuchs et al. Models of the alveolar epithelium
RU2781968C1 (en) Biomedical cell product based on mammalian mesenchymal stromal cells and hexapeptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Li Jianhui

Inventor after: Yang Zijiang

Inventor after: Zheng Jun

Inventor after: Xin Liming

Inventor before: Li Jianhui

Inventor before: Yang Zijiang

Inventor before: Zheng Jun

Inventor before: Xin Limin

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant